A retrospective analysis of mycophenolic acid and cyclosporin concentrations with acute rejection in renal transplant recipients

被引:79
|
作者
Pillans, PI
Rigby, RJ
Kubler, P
Willis, C
Salm, P
Tett, SE
Taylor, PJ
机构
[1] Princess Alexandra Hosp, Dept Clin Pharmacol, Woolloongabba, Qld 4102, Australia
[2] Univ Queensland, Princess Alexandra Hosp, Dept Med, Brisbane, Qld 4102, Australia
[3] Princess Alexandra Hosp, Renal Transplantat Unit, Woolloongabba, Qld 4102, Australia
[4] Univ Queensland, Sch Pharm, Brisbane, Qld 4072, Australia
关键词
mycophenolic acid; cyclosporin; acute rejection; renal transplantation;
D O I
10.1016/S0009-9120(00)00196-X
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Objectives: Although monitoring of cyclosporin (CsA) is standard clinical practice postrenal transplantation. mycophenolic acid (MPA) concentrations are not routinely measured. There is evidence that a relationship exists between MPA area under the concentration-time curve (AUC) and rejection. In this study, a retrospective analysis was undertaken of 27 adult renal transplant recipients. Methods: Patients received CsA and MPA therapy and had a four-point MPA AUC investigation. The relationship between MPA AUC performed in the first week after transplantation, as well as median trough cyclosporin concentrations, and clinical outcomes in the first month posttransplant were evaluated. Results: A total of 12 patients experienced biopsy proven rejection (44.4%) and 4 patients had gastrointestinal adverse events (14.8%). A statistically significant relationship was observed between the incidence of biopsy proven rejection and both MPA AUC (p = 0.02) and median trough CsA concentration (p = 0.008). No relationship between trough MPA concentration and rejection was observed (p = 0.21). Only 3 of 11 (27%) patients with an MPA AUC > 30 mg.h/L and a median trough CsA > 175 mug/L experienced acute rejection, compared with a 56% incidence of rejection for the remaining 16 patients. Patients who experienced adverse gastrointestinal events had significantly lower MPA AUC (p = 0.04), but median trough CsA concentrations were not significantly different (p = 0.24). Further, 3 of these 4 patients had rejection episodes. Conclusions: in addition to standard CsA monitoring, we propose further investigation of the use of a 4-point sampling strategy to predict MPA AUC in the first week posttransplant, which may facilitate optimization of mycophenolate mofetil dose at a rime when patients are most vulnerable to acute rejection. (C) 2001 The Canadian Society of Clinical Chemists. All rights reserved.
引用
收藏
页码:77 / 81
页数:5
相关论文
共 50 条
  • [21] SLCO1B1 genetic polymorphism influences mycophenolic acid tolerance in renal transplant recipients
    Michelon, Hugues
    Koenig, Joerg
    Durrbach, Antoine
    Quteineh, Lina
    Verstuyft, Celine
    Furlan, Valerie
    Ferlicot, Sophie
    Letierce, Alexia
    Charpentier, Bernard
    Fromm, Martin F.
    Becquemont, Laurent
    PHARMACOGENOMICS, 2010, 11 (12) : 1703 - 1713
  • [22] Mycophenolic acid concentrations in long-term heart transplant patients: relationship with calcineurin antagonists and acute rejection
    Cantin, B
    Giannetti, N
    Parekh, H
    Panchal, SN
    Kwok, BWK
    Najem, R
    Woodman, K
    Hunt, SA
    Valantine, HA
    CLINICAL TRANSPLANTATION, 2002, 16 (03) : 196 - 201
  • [23] A study of the impact of cytokine gene polymorphism in acute rejection of renal transplant recipients
    Mohammad Hossein Karimi
    Saeed Daneshmandi
    Ali Akbar Pourfathollah
    Bita Geramizadeh
    Ramin Yaghobi
    Ghanbar Ali Rais-Jalali
    Jamshid Roozbeh
    Shahram Bolandparvaz
    Molecular Biology Reports, 2012, 39 : 509 - 515
  • [24] A study of the impact of cytokine gene polymorphism in acute rejection of renal transplant recipients
    Karimi, Mohammad Hossein
    Daneshmandi, Saeed
    Pourfathollah, Ali Akbar
    Geramizadeh, Bita
    Yaghobi, Ramin
    Rais-Jalali, Ghanbar Ali
    Roozbeh, Jamshid
    Bolandparvaz, Shahram
    MOLECULAR BIOLOGY REPORTS, 2012, 39 (01) : 509 - 515
  • [25] Influence of carboxylesterase 2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients
    Fujiyama, N.
    Miura, M.
    Satoh, S.
    Inoue, K.
    Kagaya, H.
    Saito, M.
    Habuchi, T.
    Suzuki, T.
    XENOBIOTICA, 2009, 39 (05) : 407 - 414
  • [26] Pharmacokinetic Modelling of the Plasma Protein Binding of Mycophenolic Acid in Renal Transplant Recipients
    Reinier M. van Hest
    Teun van Gelder
    Arnold G. Vulto
    Leslie M. Shaw
    Ron A. A. Mathot
    Clinical Pharmacokinetics, 2009, 48 : 463 - 476
  • [27] Trough levels of mycophenolic acid and its glucuronidated metabolite in renal transplant recipients
    Merkel, U
    Lindner, S
    Vollandt, R
    Sperschneider, H
    Balogh, A
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2005, 43 (08) : 379 - 388
  • [28] Detection of acute tubulointerstitial rejection by proteomic analysis of urinary samples in renal transplant recipients
    Wittke, S
    Haubitz, M
    Walden, M
    Rohde, F
    Schwarz, A
    Mengel, M
    Mischak, H
    Haller, H
    Gwinner, W
    AMERICAN JOURNAL OF TRANSPLANTATION, 2005, 5 (10) : 2479 - 2488
  • [29] Mycophenolic Acid Pharmacokinetics in Lung Transplant Recipients With Cystic Fibrosis
    Stuckey, Linda
    Ojo, Tammy Clark
    Park, Jeong M.
    Annesley, Thomas
    Bartos, Cathy
    Cibrik, Diane M.
    THERAPEUTIC DRUG MONITORING, 2014, 36 (02) : 148 - 151
  • [30] Colchicine myopathy in renal transplant recipients on cyclosporin
    Ducloux, D
    Schuller, V
    BressonVautrin, C
    Chalopin, JM
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 1997, 12 (11) : 2389 - 2392